Skip to content

Comparative Performance of INVU™ Versus Intrauterine Pressure Catheter (IUPC) in Uterine Contractions Monitoring of Pregnant Women.

Clinical Study Evaluating the Safety of Invu ™ and Comparative Performance of Invu ™ Versus IUPC in Prenatal Monitoring of Pregnant Subjects With Uterine Contractions.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03889405
Enrollment
80
Registered
2019-03-26
Start date
2019-04-09
Completion date
2020-01-31
Last updated
2021-02-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy, Pregnant Women

Brief summary

The primary objective of this research is to assess the agreement between INVU™ and IUPC (the gold standard) during prenatal monitoring of uterine contractions and to assess the safety of INVU™. Additional information comparing INVU™ to TOCO (the standard of care) was also collected.

Detailed description

This multi-center, prospective, comparative, open-label study will be performed in two steps: A training step where up to 40 subjects will be enrolled to confirm uterine contraction performance level. In the second, validation step, the performance of the uterine contraction detection algorithm will be validated. The validation phase will involve up to 80 subjects. Sub-study will be implemented in the sites that will monitor the uterine activity of the subjects with TOCO, in addition to INVU™ and IUPC. Following the screening process, participants subject will undergo continuous recording of the uterine contraction and the fetal heart rate (FHR) for 30 to 60 min using INVU™, Cardiotocograph ((TOCO / CTG), and Intrauterine Pressure Catheters (IUPC). The collected data will be downloaded and comprehensive analysis of the values will be performed offline. Each participant will undergo continuous monitoring by the medical team to identify any safety issue, including but not limited to irritation, sensitization, and potential harmful misuse.

Interventions

DEVICEINVU™

The subject will undergo continuous recording of the uterine contractions and the fetal heart rate (FHR) for 30 to 60 min using INVU™.

DEVICEIUPC

The study participants will undergo continuous recording of the uterine contractions by IUPC.

DEVICETOCO

Some of the study participants will undergo continuous recording of the uterine contractions and the fetal heart rate (FHR) by TOCO as well.

Sponsors

Nuvo-Group, Ltd.
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

* Female age between 18-50 * Gestational age ≥32 + 0 weeks * Singleton gestation * Ability to understand and sign informed consent * The subject is within the first stage labor, including early, active and transition phases (cervix is dilated up to 10 cm) * The subject has an IUPC in place for clinical contraction monitoring *

Exclusion criteria

* BMI ≥50 and 15≤ prior pregnancy (Body Mass Index) * Multiple gestation * Uncontrolled Hypertension * Known fetal Anomaly (i.e. major structural) * Subjects with skin problems in the abdominal area (such as flesh wounds, cuts in the skin, skin rashes, etc.) * Subjects with implanted electronic devices (pacemaker, defibrillator, etc.) * Subjects who, in the judgment of the investigator, are likely to be non-compliant or uncooperative during the study * Subject who is within the second stage labor (cervix is fully dilated to 10 cm or going into the second stage of labor or more)

Design outcomes

Primary

MeasureTime frameDescription
Assessment of the agreement between INVU™ and IUPC (the gold standard) during monitoring of uterine contractions as well as the agreement between Cardiotocography (TOCO) and IUPC, where applicable.30-60 minutes per participantThree blinded assessors will review the uterine contractions output data (the recordings) from the monitoring devices and determine for each time point whether a contraction occurred. The assessors will not have visibility to the source of the recorded data. Each assessor will review the sessions in a randomized order, while the evaluation will include: a contraction start point, peak, and endpoint. The actual presence of a contraction will be determined by the IUPC.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 20, 2026